Biomarkers For The Treatment And Prognosis Of Sight-threatening Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$598,305.00
Summary
Diabetic retinopathy (DR) is a highly specific vascular complication of both type 1 and type 2 diabetes, with prevalence strongly related to the duration of diabetes. Clinic biomarkers of DR have become the basis for preventive medicine. In this project, we aim to evaluate possible biomarkers in both Chinese and Australian diabetic populations at different stages of DR. We will also investigate pathological mechanisms and novel drugs to treat DR in animal models.
Dementia is the third leading cause of death in Australia and the single greatest cause of disability in the elderly. Current therapies for Alzheimer’s disease (AD), the most common form of dementia, are inadequate and fundamentally new treatment approaches are required. The aim of this proposal is to develop novel drug candidates for the treatment and prevention of AD and other neurodegenerative disorders by targeting a class of cell-surface receptors called G protein-coupled receptors (GPCRs).
Alzheimer’s disease (AD), is the most common form of dementia, accounting for between 50-70% of all cases. There is general agreement that current treatments for AD/dementia are inadequate so new treatment strategies are desperately needed. I am addressing these challenges by developing new technologies to generate next generation treatments for AD.